Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd

₹ 67.2 -8.57%
17 Jul - close price
About

Incorporated in 2019, Asston Pharmaceuticals Ltd is in the business of manufacturing pharmaceutical products.[1]

Key Points

Business Overview:[1]
APL offers pharmaceutical products in the form of Tablet, Capsules, Syrup, Sachet and Injection (LVP and SVP). The company has WHO GMP approved manufacturing units for manufacturing
the entire products range and also has
a tie up with a NABL Accredited Laboratory.

  • Market Cap 57.2 Cr.
  • Current Price 67.2
  • High / Low 126 / 61.0
  • Stock P/E 14.8
  • Book Value 45.6
  • Dividend Yield 0.00 %
  • ROCE 16.8 %
  • ROE 15.5 %
  • Face Value 10.0

Pros

  • Company has reduced debt.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Earnings include an other income of Rs.6.12 Cr.
  • Company has high debtors of 524 days.
  • Working capital days have increased from 259 days to 434 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Figures in Rs. Crores

Sep 2024 Mar 2025 Sep 2025 Mar 2026
15.97 9.07 15.42 10.05
13.71 5.89 13.19 12.85
Operating Profit 2.26 3.18 2.23 -2.80
OPM % 14.15% 35.06% 14.46% -27.86%
0.64 -0.07 -1.86 4.63
Interest 0.42 0.53 0.28 0.36
Depreciation 0.02 0.02 0.07 0.25
Profit before tax 2.46 2.56 0.02 1.22
Tax % 22.76% 23.44% -50.00% 59.84%
1.90 1.95 0.03 0.48
EPS in Rs 24.24 3.11 0.04 0.56
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
9.60 6.54 16.03 25.04 25.47
9.96 5.02 12.21 19.60 26.04
Operating Profit -0.36 1.52 3.82 5.44 -0.57
OPM % -3.75% 23.24% 23.83% 21.73% -2.24%
0.96 0.65 0.25 0.57 6.12
Interest 0.43 0.72 0.76 0.95 0.63
Depreciation 0.01 0.04 0.06 0.04 0.32
Profit before tax 0.16 1.41 3.25 5.02 4.60
Tax % 31.25% 25.53% 25.23% 23.11% 15.87%
0.11 1.06 2.43 3.85 3.87
EPS in Rs 1.57 15.14 31.00 6.14 4.55
Dividend Payout % -0.00% -0.00% -0.00% -0.00% -0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 57%
TTM: 2%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 54%
TTM: 2%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -44%
Return on Equity
10 Years: %
5 Years: 28%
3 Years: 26%
Last Year: 16%

Balance Sheet

Figures in Rs. Crores

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.70 0.70 0.78 6.27 8.51
Reserves 0.23 1.29 6.40 4.76 30.35
3.31 5.24 6.82 7.25 5.11
5.25 6.46 6.70 9.84 7.68
Total Liabilities 9.49 13.69 20.70 28.12 51.65
0.92 1.13 0.97 0.96 10.69
CWIP -0.00 -0.00 -0.00 -0.00 -0.00
Investments -0.00 -0.00 -0.00 -0.00 -0.00
8.57 12.56 19.73 27.16 40.96
Total Assets 9.49 13.69 20.70 28.12 51.65

Cash Flows

Figures in Rs. Crores

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-1.19 -0.32 -3.97 -0.03 -10.18
-0.00 -0.91 -0.01 0.73 -9.91
1.29 1.21 3.86 -0.51 21.18
Net Cash Flow 0.10 -0.01 -0.12 0.19 1.09
Free Cash Flow -1.19 -0.57 -3.98 -0.06 -20.24
CFO/OP 322% -20% -92% -0% 1,368%

Ratios

Figures in Rs. Crores

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 243.33 480.53 380.71 357.86 524.07
Inventory Days 27.24 204.29 53.91 18.59 16.14
Days Payable 246.78 754.51 217.50 154.11 120.76
Cash Conversion Cycle 23.79 -69.70 217.12 222.34 419.45
Working Capital Days -12.17 43.53 162.80 178.86 434.22
ROCE % 37.14% 37.78% 36.62% 16.80%

Insights

In beta
Mar 2023 Mar 2024 May 2025
Export Revenue (% of Total Sales)
%

Log in to view insights

Please log in to see hidden values.

Login
Pharmaceuticals Sales (% of Total Sales)
%
Sierra Leone Revenue (% of Total Sales)
%
Top 5 Customer Concentration (% of Revenue)
%
Total Production Volume
MT
Number of Registered Product Brands
count
Order Book
USD

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

3 Recently
Sep 2025Mar 2026
50.66% 50.66%
6.04% 1.91%
43.30% 47.41%
No. of Shareholders 751687

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents